Nanoparticle comprising rapamycin and albumin as anticancer agent

2-3. (canceled)

(canceled)

10-15. (canceled)

(canceled)

A unit dosage form for treatment of cancer comprising (a) nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof, wherein the amount of the rapamycin or derivative thereof in the unit dosage form is in the range of about 180 mg to about 270 mg, and (b) a pharmaceutically acceptable carrier.

22-31. (canceled)

A kit comprising (a) nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof, wherein the amount of the rapamycin or derivative thereof in the kit is in the range of about 180 mg to about 270 mg, and (b) instructions for using the kit in treating cancer.

33-43. (canceled)

A method of treating cancer in an individual comprising (a) a first therapy comprising administering to the individual an effective amount of a composition comprising nanoparticles that comprise rapamycin or a derivative thereof and a carrier protein and (b) a second therapy selected from the group consisting of chemotherapy, radiation therapy, surgery, hormone therapy, gene therapy, immunotherapy, bone marrow transplantation, stem cell transplantation, targeted therapy, cryotherapy, ultrasound therapy, and immunotherapy.

47-53. (canceled)

56-57. (canceled)

59-61. (canceled)

63-64. (canceled)

(canceled)

The method of claim 72, wherein AKT kinase inhibitor is perifosine.